These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36146461)

  • 1. Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination.
    Bhatnagar N; Kim KH; Subbiah J; Park BR; Wang P; Gill HS; Wang BZ; Kang SM
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Ko EJ; Lee Y; Lee YT; Kim YJ; Kim KH; Kang SM
    Antiviral Res; 2018 Aug; 156():107-115. PubMed ID: 29885376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
    Bhatnagar N; Kim KH; Subbiah J; Park BR; Ko EJ; Seong BL; Kang SM
    Antiviral Res; 2022 Jan; 197():105229. PubMed ID: 34933043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge.
    Boravleva EY; Lunitsin AV; Kaplun AP; Bykova NV; Krasilnikov IV; Gambaryan AS
    Biochemistry (Mosc); 2020 May; 85(5):553-566. PubMed ID: 32571185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1.
    Kim H; Yu J; Bai D; Nahm MH; Wang P
    Front Immunol; 2022; 13():1079047. PubMed ID: 36578488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.
    Ko EJ; Lee YT; Kim KH; Jung YJ; Lee Y; Denning TL; Kang SM
    J Virol; 2016 Aug; 90(15):6976-6988. PubMed ID: 27226368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
    Layton RC; Gigliotti A; Armijo P; Myers L; Knight J; Donart N; Pyles J; Vaughan S; Plourde J; Fomukong N; Harrod KS; Gao P; Koster F
    PLoS One; 2011; 6(6):e20641. PubMed ID: 21687736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
    J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
    Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.
    Luo J; Liu XP; Xiong FF; Gao FX; Yi YL; Zhang M; Chen Z; Tan WS
    Front Immunol; 2019; 10():2274. PubMed ID: 31611875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.